Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharmaust Limited (DE:ECQ0)
FRANKFURT:ECQ0
Holding DE:ECQ0?
Track your performance easily
ECQ0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.04 - €0.25
Previous Close€0.11
Volume0.00
Average Volume (3M)N/A
Market Cap
€58.32M
Enterprise Value€57.69M
Total Cash (Recent Filing)AU$2.42M
Total Debt (Recent Filing)AU$1.39M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Feb 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)8.76
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.26Price Target Upside142.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Pharmaust Limited News
PremiumCompany Announcements
Neurizon Therapeutics Updates Securities Trading Policy
PremiumCompany Announcements
Neurizon Therapeutics Corrects Announcement on ALS Drug
PremiumCompany Announcements
Neurizon Therapeutics Explores Promising ALS Treatment
PremiumCompany Announcements
Neurizon Therapeutics Announces Promising ALS Drug ResultsOptions Prices
Currently, No data available
---
Ownership Overview
ECQ0 FAQ
What was Pharmaust Limited’s price range in the past 12 months?
Pharmaust Limited lowest stock price was €0.04 and its highest was €0.25 in the past 12 months.
What is Pharmaust Limited’s market cap?
Currently, no data Available
When is Pharmaust Limited’s upcoming earnings report date?
Pharmaust Limited’s upcoming earnings report date is Feb 27, 2025 which is in 96 days.
How were Pharmaust Limited’s earnings last quarter?
Pharmaust Limited released its earnings results on Aug 30, 2024. The company reported -€0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.01.
Is Pharmaust Limited overvalued?
According to Wall Street analysts Pharmaust Limited’s price is currently Undervalued.
Does Pharmaust Limited pay dividends?
Pharmaust Limited does not currently pay dividends.
What is Pharmaust Limited’s EPS estimate?
Pharmaust Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaust Limited have?
Pharmaust Limited has 491,705,780 shares outstanding.
What happened to Pharmaust Limited’s price movement after its last earnings report?
Pharmaust Limited reported an EPS of -€0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of Pharmaust Limited?
Currently, no hedge funds are holding shares in DE:ECQ0
---
Pharmaust Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€0.26 (142.99% Upside)
€0.26 (142.99% Upside)
Blogger Sentiment
Bullish
DE:ECQ0 Sentiment 99%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth €530.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
148.83%
12-Months-Change
Fundamentals
Return on Equity
-123.71%
Trailing 12-Months
Asset Growth
85.34%
Trailing 12-Months
Company Description
Pharmaust Limited
PharmAust Ltd operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries.
---
ECQ0 Stock 12 Month Forecast
Average Price Target
€0.26
▲(142.99% Upside)
Technical Analysis
Mister Spex SE
―
Bod Australia Ltd
―
IDT Australia Limited
―
Medical Developments International Limited
―
Best Analysts Covering ECQ0
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+25.25%
reiterated a buy rating 20 days ago
Copying Iain Wilkie's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +25.25% per trade.
---